

Elaine Gray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6206157/publications.pdf>

Version: 2024-02-01

25
papers

1,008
citations

687363

13
h-index

752698

20
g-index

25
all docs

25
docs citations

25
times ranked

1632
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiplex genome editing of mammalian cells for producing recombinant heparin. <i>Metabolic Engineering</i> , 2022, 70, 155-165.	7.0	5
2	Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors'™ Organisation guideline. <i>Haemophilia</i> , 2022, 28, 515-519.	2.1	7
3	International multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3177-3192.	3.8	20
4	Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors'™ Organisation guideline. <i>Haemophilia</i> , 2020, 26, 6-16.	2.1	31
5	Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline. <i>Haemophilia</i> , 2020, 26, 151-155.	2.1	44
6	Summary of the WHO hearing on the development of product-specific reference materials for coagulation factor VIII and factor IX products. <i>Biologicals</i> , 2020, 67, 88-93.	1.4	3
7	The traceability of commercial plasma calibrators to the plasma International Standards for factor VIII and factor IX. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 810-818.	1.3	3
8	Enabling accurate measurement of activated factor XI (FXIa) in therapeutic immunoglobulin products. <i>Vox Sanguinis</i> , 2020, 116, 656-664.	1.5	0
9	Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood. <i>PLoS ONE</i> , 2020, 15, e0233644.	2.5	37
10	Animal models of mechanisms of <sc>SARS-CoV-2</sc> infection and <sc>COVID-19</sc> pathology. <i>British Journal of Pharmacology</i> , 2020, 177, 4851-4865.	5.4	158
11	Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. <i>British Journal of Haematology</i> , 2020, 191, 347-362.	2.5	32
12	Activity measurements of dalcinonacog alfa. <i>Haemophilia</i> , 2020, 26, 346-353.	2.1	6
13	Title is missing!. , 2020, 15, e0233644.		0
14	Title is missing!. , 2020, 15, e0233644.		0
15	Title is missing!. , 2020, 15, e0233644.		0
16	Title is missing!. , 2020, 15, e0233644.		0
17	Potency estimates for recombinant factor IX in the one-stage clotting assay are influenced by more than just the choice of activated partial thromboplastin time reagent. <i>Haemophilia</i> , 2018, 24, e363-e368.	2.1	6
18	Precipitation and Neutralization of Heparin from Different Sources by Protamine Sulfate. <i>Pharmaceuticals</i> , 2017, 10, 59.	3.8	19

#	ARTICLE	IF	CITATIONS
19	Biochemical and functional characterization of glycosaminoglycans released from degranulating rat peritoneal mast cells: Insights into the physiological role of endogenous heparin. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 41, 96-102.	2.6	5
20	The US regulatory and pharmacopeia response to the global heparin contamination crisis. <i>Nature Biotechnology</i> , 2016, 34, 625-630.	17.5	93
21	Pharmacology of Heparin and Related Drugs. <i>Pharmacological Reviews</i> , 2016, 68, 76-141.	16.0	250
22	Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity. <i>Thrombosis and Haemostasis</i> , 2014, 112, 932-940.	3.4	54
23	The Anticoagulant and Antithrombotic Mechanisms of Heparin. <i>Handbook of Experimental Pharmacology</i> , 2012, , 43-61.	1.8	111
24	Protamine neutralisation of low molecular weight heparins and their oligosaccharide components. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 399, 763-771.	3.7	52
25	Characterization of Unfractionated Heparin: Comparison of Materials from the last 50 Years. <i>Thrombosis and Haemostasis</i> , 2000, 84, 1052-1056.	3.4	72